ArticleAmerican journal of translational research2026
Total parathyroidectomy with autotransplantation vs. subtotal parathyroidectomy for secondary hyperparathyroidism: lower recurrence rates but comparable cardiovascular outcomes.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to compare the long-term efficacy and cardiovascular outcomes of total parathyroidectomy with autotransplantation (TPTX+AT) versus subtotal parathyroidectomy (SPTX) in maintenance hemodialysis (MHD) patients with refractory secondary hyperparathyroidism (SHPT).
methodsThis retrospective cohort study enrolled MHD patients with SHPT who underwent parathyroidectomy between January 2020 and December 2022, with follow-up through December 2025. Patients were divided into TPTX+AT and SPTX groups. Serum intact parathyroid hormone (iPTH), corrected calcium, phosphorus, alkaline phosphatase, and 25-hydroxyvitamin D were measured preoperatively, on postoperative day 1, and at 3, 6, 12, and 36 months. Operative time, hospital stay, early complications, and long-term outcomes including SHPT recurrence, mortality, cardiovascular events, and permanent hypoparathyroidism were recorded.
resultsOf 217 patients, 113 underwent TPTX+AT and 104 underwent SPTX. Operative time was longer with TPTX+AT (129.42 ± 34.74 min vs. 114.49 ± 29.71 min,
conclusionTPTX+AT achieves more durable biochemical control and lower SHPT recurrence but carries a definite risk of permanent hypoparathyroidism, with equivalent survival and cardiovascular outcomes, underscoring the need for individualized surgical selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.